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Abstract
Dendritic cell (DC) activation is commonly used as a measure of the immunomodulatory potential of candidate exogenous
and endogenous molecules. Residual lipopolysaccharide (LPS) contamination is a recurring theme and the potency of LPS is
not always fully appreciated. To address this, polymyxin B (PmB) is often used to neutralise contaminating LPS. However, the
limited capacity of this antibiotic to successfully block these effects is neglected. Therefore, this study aimed to determine
the minimum LPS concentration required to induce murine bone marrow-derived dendritic cell (BMDC) maturation and
cytokine secretion and to assess the ability of PmB to inhibit these processes. LPS concentrations as low as 10 pg/ml and
20 pg/ml induced secretion of interleukin (IL)-6 and tumor necrosis factor (TNF)-a respectively, while a concentration of
50 pg/ml promoted secretion of IL-12p40. A much higher threshold exists for IL-12p70 as an LPS concentration of 500 pg/
ml was required to induce secretion of this cytokine. The efficacy of PmB varied substantially for different cytokines but this
antibiotic was particularly limited in its ability to inhibit LPS-induced secretion of IL-6 and TNF-a. Furthermore, an LPS
concentration of 50 pg/ml was sufficient to promote DC expression of costimulatory molecules and PmB was limited in its
capacity to reverse this process when LPS concentrations of greater than 20 ng/ml were used. There is a common
perception that LPS is heat resistant. However, heat treatment attenuated the ability of low concentrations of LPS to induce
secretion of IL-6 and IL-12p40 by BMDCs, thus suggesting that heat-inactivation of protein preparations is also an ineffective
control for discounting potential LPS contamination. Finally, LPS concentrations of less than 10 pg/ml were incapable of
promoting secretion of IL-6 independently but could synergise with heat-labile enterotoxin (LT) to promote IL-6, indicating
that reducing contaminating endotoxin concentrations to low pg/ml concentrations is essential to avoid misleading
conclusions regarding candidate immunomodulators.
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Introduction
Lipopolysaccharide (LPS) is a major component of the outer
membrane of Gram-negative bacteria. This pyrogen is essential in
maintaining the structural integrity of bacteria and repelling
antimicrobial responses. LPS is a potent endotoxin comprised of
a repetitive glycan polymer referred to as the O-antigen, which is
connected to the core polysaccharide. The core domain is directly
attached to Lipid A which is a phosphorylated glucosamine
disaccharide containing multiple fatty acids which serve to secure
the LPS molecule to the bacterial membrane. LPS is a pathogen-
associated molecular pattern (PAMP) known to signal through the
CD14/Toll-like receptor (TLR) 4/myeloid differentiated protein
(MD)-2 receptor complex, thereby promoting innate immune
responses characterised by rapid secretion of proinflammatory
cytokines and chemokines [1–4]. Importantly, the Lipid A moiety
is mainly responsible for these immunostimulatory effects [5–6].
In studies assessing the effects of candidate microbial and
endogenous immunomodulators, LPS contamination of sample
preparations has proven to be a hugely significant problem, often
resulting in misleading and inaccurate conclusions. For example,
one need look no further than the ambiguities associated with
many of the more established endogenous ‘danger signals’
identified thus far in order to gauge the magnitude of the problem
concerning residual LPS contamination [7].
In 1999, an immunomodulatory role for high-mobility group
box protein 1 (HMGB1) was proposed; stimulation of monocyte
cultures with HMGB1 induced secretion of a range of proin-
flammatory mediators including tumor necrosis factor (TNF)-a,
interleukin (IL)-1b, IL-1a, IL-1 receptor antagonist (ra), IL-6, IL-8,
macrophage inflammatory protein (MIP)-1a and MIP-1b.
HMGB1 has since been shown to play important roles in both
innate and adaptive immunity [8–12]. However, recent studies
have contradicted many of the above findings, demonstrating that
a highly purified form of recombinant HMGB1 fails to induce
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Furthermore, the direct proinflammatory activity of HMGB1
reported previously and described above is likely to be a result of
contamination with bacterial components as most of these studies
were carried out using recombinant HMGB1 derived from
Escherichia coli (E. coli) expression systems. Heat shock protein
(Hsp) 60, Hsp70, Hsp90 and glycoprotein (gp) 96 have all been
reported to stimulate dendritic cell (DC) [14–17] and macrophage
activation [16,18–20]. However, Wallin and colleagues noted that
highly purified murine liver Hsp70 failed to stimulate cytokine
secretion from murine DCs. In contrast, a Hsp70 preparation
contaminated with low levels of LPS induced cytokine secretion at
concentrations as low as 50ng/ml, and these effects were not
inhibited by PmB and were also heat-sensitive [21]. In recent years
many reports have been published which consistently outline the
failure of highly purified Hsp molecules to stimulate immune
responses in the absence of contaminating PAMPs. [21–24].
In vitro, heparan sulfate degradation products and hyaluronic
acid fragments stimulate activation of DCs and endothelial cells
[25–26]. However, many studies have reported a role for TLR4
[26–27], and to a lesser extent TLR2 [28], in regulating the
alarmin function of these fragments. Despite these encouraging
studies, caution must be warranted given that these fragments
signal through TLR4. These concerns are heightened by the
finding that highly purified pharmacological-grade hyaluronic acid
fragments fail to induce NF-kB activation or cytokine secretion in
murine macrophages [29].
DC activation, as measured by cytokine secretion and increased
expression of costimulatory and major histocompatibility complex
(MHC) molecules, is commonly used as a measure of the potency
of candidate immunomodulators, particularly endogenous danger
signals. However, it is important to note that many recombinant
protein preparations are derived from bacterial expression
systems. Thus, residual LPS contamination is a significant issue
and the potency of LPS is not always fully appreciated. To address
this, polymyxin B (PmB) is often used to neutralise contaminating
LPS. However, the limited capacity of this antibiotic to successfully
block these effects is neglected. Therefore, in order to characterise
the immunomodulatory effects of candidate molecules with
confidence, it is crucial to address this key issue. This study aimed
to determine the minimum LPS concentration required to induce
DC maturation and cytokine secretion, and to assess the ability of
PmB to inhibit these processes.
Materials and Methods
Medium
Roswell Park Memorial Institute (RPMI) 1640 medium
(Biosera) was supplemented with 2 mM L-Glutamine (Gibco),
50 units/ml penicillin (Gibco), 50 mg/ml streptomycin (Gibco)
and 8% (v/v) heat-inactivated (56uC for 30 minutes) foetal calf
serum (Biosera).
Cell Culture
Female BALB/c mice were obtained from Harlan Olac
(Bicester, U.K.) and were used at 8–16 weeks of age. Animals
were maintained according to the regulations of the European
Union and the Irish Department of Health. This study was
approved by the Trinity College Dublin Animal Research Ethics
Committee (Reference Number 091210). Bone marrow-derived
dendritic cells (BMDCs) were generated as described previously
[30]. Cells were plated out on day 10 and were stimulated on
day 11. The specific treatments and conditions for stimulation of
BMDCs are outlined in each experimental figure legend. Super-
natants were collected 24 hours later for analysis of cytokine levels
by enzyme-linked immunosorbent assay (ELISA). Following the
removal of supernatants, the cells were harvested and assessed for
toxicity and expression of surface markers by flow cytometry.
Flow Cytometry
Cells were incubated for 30 minutes with AQUA fluorescent
dye (0.5 ml) (Invitrogen) and then incubated for an additional
30 minutes with anti-CD11c (0.3 mg/ml, BD Pharmingen) and
antibodies specific for CD80 (2.5 mg/ml), CD40 (2.5 mg/ml) and
MHC class II (0.2 mg/ml) (BD Pharmingen). Samples were
acquired using summit software (Dako, Colorado) and the data
were analysed using FlowJo
TM software (Treestar, Oregon).
Measurement of Cytokine Levels by ELISA
Concentrations of the cytokines IL-6, IL-12p40 and IL-12p70
were measured using ELISA antibodies obtained from BD
Pharmingen. Concentrations of the cytokine TNF-a were mea-
sured using a commercially available ELISA kit (R&D systems).
The OD values were obtained using a microtitre plate reader
measuring absorbance at 492 nm, while the cytokine concentra-
tions were determined using a standard curve.
Polymyxin B
A range of concentrations of LPS from E. coli, Serotype R515,
TLRgrade (Enzo Life Sciences) were incubated on a rotator for
2 hours at 37uC with 100 mg/ml PmB (Sigma). These treatments
were then used to stimulate BMDCs.
Escherichia coli heat-labile enterotoxin
E. coli heat-labile enterotoxin was kindly provided by Dr. Takao
Tsuji (Department of Microbiology, School of Medicine, Fujita
Health University, Aichi, Japan). This heat-labile enterotoxin was
passed through three separate endotoxin removal columns (Pierce)
three times each. Endotoxin level was subsequently measured
using the limulus amebocyte lysate assay (Pierce) and was
determined to be 0.049pg of endotoxin per mg of heat-labile
enterotoxin.
Statistical Analysis
Cytokine concentrations were compared by one-way ANOVA.
Where significant differences were found, the Tukey-Kramer
multiple comparisons test was used to identify differences between
individual groups.
Results
Different thresholds exist for secretion of specific
cytokines by DCs in response to LPS
In order to assess proinflammatory cytokine secretion by DCs in
response to LPS, murine BMDCs were stimulated with concen-
trations from 1 pg/ml to 1 mg/ml E. coli LPS. LPS concentrations
as low as 10 pg/ml and 20 pg/ml were sufficient to induce
secretion of IL-6 (Figure 1A) and TNF-a (Figure 1B) respectively,
while maximal secretion of these cytokines was evident when
a concentration of 500 pg/ml LPS was added (Figure 1A, 1B).
LPS concentrations of 50pg/ml and 500 pg/ml were required
to promote detectable secretion of IL-12p40 (Figure 1C) and IL-
12p70 (Figure 1D) respectively, while maximal secretion of both of
these cytokines was reached following stimulation with 50 ng/ml
LPS (Figure 1C, 1D).
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DC surface expression of MHC class II and costimulatory
molecules
DC activation is also characterised by increased expression of
surface markers, including CD80, CD40 and MHC class II, in
a process referred to as maturation. In order to evaluate the dose
response of DC maturation by LPS, murine BMDCs were
stimulated with concentrations from 1 pg/ml to 1 mg/ml LPS. A
concentration as low as 50pg/ml LPS was sufficient to upregulate
surface expression of CD80, CD40 and MHC class II (Figure 2).
Furthermore, maximal DC maturation was achieved when an LPS
concentration of 1ng/ml was used (Figure 2).
10mg/ml PmB is the optimal concentration for inhibiting
LPS-induced DC activation
PmB is often used to neutralise contaminating LPS in sample
preparations and therefore to eliminate the possibility that residual
LPS may be responsible for any immunostimulatory effects
observed. In order to determine the optimal PmB concentration
for treating murine BMDCs without eliciting toxicity or matura-
tion, these cells were stimulated with concentrations from 0.01 mg/
ml to 500 mg/ml PmB. Notably, concentrations of 100 mg/ml
PmB and higher were toxic to BMDCs (Figure 3A) and
a concentration of 50 mg/ml PmB was sufficient to enhance
expression of CD80, CD40 and MHC II (Figure 3B). Therefore,
10 mg/ml PmB was determined to be the optimal concentration
for inhibiting LPS-induced BMDC activation without having any
direct effect on the cells.
The ability of PmB to reverse secretion of
proinflammatory cytokines by DCs in response to LPS is
cytokine-dependent
In order to assess the ability of PmB to inhibit proinflammatory
cytokine secretion by DCs in response to LPS, murine BMDCs
were stimulated with concentrations from 1pg/ml to 1mg/ml LPS,
which were pre-incubated alone or in the presence of 100 mg/ml
PmB for 2 hours at 37uC. Following pre-incubation of LPS with
PmB, the final concentration of PmB added to the cells was 10 mg/
ml.
The efficacy of PmB in suppressing secretion of proinflamma-
tory cytokines was cytokine-dependent. When measuring IL-6, the
inhibitory properties of PmB began to subside when LPS
concentrations greater than 1 ng/ml were used. Furthermore,
the ability of PmB to inhibit IL-6 secretion continued to decrease
proportionally with increasing LPS concentrations until it was
completely ineffective at concentrations greater than 50 ng/ml
Figure 1. LPS concentrations as low as 10pg/ml induce secretion of proinflammatory cytokines by murine BMDCs. BMDCs
(6.25610
5 cells/ml) from BALB/c mice were stimulated with concentrations from 1 pg/ml to 1mg/ml LPS. Supernatants were collected 24 hours later
and tested for IL-6 (A), TNF-a (B), IL-12p40 (C) and IL-12p70 (D) by ELISA. Results are mean cytokine concentrations (+ SEM) for triplicate samples.
Versus RPMI alone, *** p,0.001. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0037261.g001
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a production was limited at LPS concentrations higher than 1 ng/
ml. Moreover, following a steady decline in efficacy coinciding
with increased concentrations of LPS, PmB was rendered entirely
redundant when concentrations greater than 200 ng/ml LPS were
used (Figure 4B). In contrast, the inhibitory properties of PmB on
IL-12p40 and IL-12p70 were almost completely preserved until
LPS concentrations of 20 ng/ml (Figure 4C) and 1mg/ml
(Figure 4D) were used respectively.
PmB is limited in its capacity to inhibit DC maturation in
response to LPS
In order to assess the ability of PmB to inhibit DC maturation in
response to LPS, murine BMDCs were stimulated with concen-
trations from 1 pg/ml to 1 mg/ml LPS, which was pre-incubated
alone or in the presence of 100 mg/ml PmB for 2 hours at 37uC.
Again, the final concentration of PmB added to the cells was
10 mg/ml. Importantly, LPS-driven DC maturation was no longer
completely inhibited by PmB at concentrations greater than
20 ng/ml (Figure 5A). Furthermore, the efficacy of PmB in
suppressing this effect decreased proportionally with increasing
concentrations of LPS (Figure 5B).
Following heat treatment, low concentrations of LPS fail
to promote secretion of the proinflammatory cytokines
IL-6 and IL-12p40 by BMDCs
A second strategy used to determine if contaminating LPS is
responsible for immunomodulatory effects is heat-inactivation of
the protein [31–33]. Following heating to high temperatures
a protein is presumed to become unstable and thus inactivated,
whereas any LPS present in the preparation remains stable and
intact. It can therefore be inferred that if the immunostimulatory
response persists after heat-inactivation, it is a direct result of LPS
contamination. Conversely, if the response is no longer observed
after heat-inactivation then the protein is deemed to mediate the
response rather than any contaminating LPS. However, Gao and
colleagues have previously shown that following heat treatment,
low concentrations of LPS fail to promote secretion of TNF-a by
murine macrophages [22–23].
As mentioned above, secretion of proinflammatory cytokines by
BMDCs, particularly IL-6 and IL-12p40, is often used as a means
to assess the immunomodulatory potential of candidate microbial
and endogenous immunomodulators. In order to determine the
effect of heat treatment on the ability of low concentrations of LPS
to promote secretion of IL-6 and IL-12p40 by murine BMDCs,
these primary cells were stimulated with LPS or heat-inactivated
LPS (100uCo r6 0 uC). A concentration of 50pg/ml LPS induced
secretion of IL-6 and IL-12p40 by BMDCs, but this response was
attenuated when heat-inactivated LPS was used (Figure 6).
5pg/ml LPS is sufficient to promote secretion of the
proinflammatory cytokine IL-6 in the presence of E. coli
heat-labile enterotoxin
Some of the more established endogenous danger signals, such
as HMGB1, Hsps and small breakdown products of hyaluronic
acid, have been reported to synergise with TLR agonists to
promote a more potent inflammatory response than that
generated against either component alone [34–37]. Furthermore,
bacterial toxins including cholera toxin (CT), pneumolysin (PLY)
and heat-labile enterotoxin (LT) can also elicit synergistic effects
when used in combination with TLR agonists, in particular
enhancing BMDC secretion of IL-6 [38–39]. This suggests that
contaminating LPS concentrations which are incapable of pro-
moting BMDC secretion of proinflammatory cytokines indepen-
dently may synergise with candidate immunomodulators to
enhance this effect, thus reducing even further the minimal LPS
concentration required for BMDC activation.
In order to establish if concentrations of LPS that are incapable
of promoting cytokine secretion by BMDCs independently can
synergise with a bacterial toxin to potentiate cytokine secretion,
BMDCs were stimulated with suboptimal concentrations of LPS,
either alone or in the presence of LT. Subsequently, BMDC
secretion of IL-6 was measured. The presence of LT significantly
augmented IL-6 secretion from BMDCs in response to as little as
5 pg/ml LPS which did not activate BMDCs in the absence of LT
(Figure 7).
Discussion
Dendritic cells are professional antigen-presenting cells (APCs)
capable of linking innate and adaptive immunity. Following
Figure 2. LPS concentrations as low as 50pg/ml increase
expression of CD80, CD40 and MHC II on DCs. BMDCs were
stimulated for 24 hours with the indicated concentrations of LPS and
CpG. Cells were analysed for expression of CD80, CD40 and MHC II by
flow cytometry. Immunofluorescence is shown for LPS- or CpG-treated
BMDCs (black line) compared to untreated cells (grey histograms). Data
are representative of three independent experiments.
doi:10.1371/journal.pone.0037261.g002
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duction cascades culminating in the synthesis and secretion of
cytokines involved in promoting the onset of innate immunity and
modulating subsequent effector T cell responses. Importantly, DCs
have been classified into two discrete functional states, with each
expressing a distinct phenotype. Immature DCs are highly efficient
at antigen capture and processing, while mature DCs are potent
APCs specialised for subsequent interactions with naive T cells
[40–41]. DC activation is characterised by elevated surface
expression of costimulatory molecules, including CD80 and
CD40 as well as MHC molecules [42] in a process referred to
as maturation. Interestingly, the term ‘mature’ is commonly used
to describe DCs expressing high surface levels of costimulatory and
MHC molecules, but is also used to describe immunogenic DCs
capable of initiating adaptive immunity to foreign antigens. The
discovery that non-immunogenic or immature DCs can also
express elevated surface costimulatory and MHC molecules has
been the main focus of recent reports which have questioned the
apparent simplicity and transposable use of this terminology [42].
However, for the purpose of this study the term ‘maturation’ was
used exclusively to define elevated expression of costimulatory and
MHC molecules on the surface of BMDCs.
DC activation is often used as a means of determining the
immunomodulatory properties of both PAMPs and host-derived
danger signals. However, candidate danger signals are commonly
purified from bacterial expression systems, particularly E. coli, and
are frequently contaminated with bacterial PAMPs, especially
LPS. Despite this problematic issue, many studies have failed to
appreciate the potency of LPS and the profound ability of residual
LPS contamination to induce DC activation.
In order to raise awareness of the potency of residual LPS, this
study evaluated the dose response of DC activation by this PAMP.
LPS concentrations as low as 10 pg/ml and 20 pg/ml were
sufficient to induce BMDC secretion of the proinflammatory
Figure 3. PmB concentrations greater than 10mg/ml are toxic and increase expression of costimulatory molecules on BMDCs. BMDCs
were stimulated for 24 hours with the indicated concentrations of PmB. (A) Cells were stained with AQUA reactive dye and were analysed by flow
cytometry. (B) Cells were also analysed for expression of CD80, CD40 and MHC II by flow cytometry. Immunofluorescence is shown for PmB-treated
BMDCs (black line) compared to untreated cells (grey histograms). Data are representative of five independent experiments.
doi:10.1371/journal.pone.0037261.g003
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tration of 50 pg/ml LPS was adequate to enhance expression of
costimulatory and MHC II molecules. The magnitude of both
costimulatory molecule expression and cytokine secretion in-
creased dramatically with elevated concentrations of LPS.
However, with regard to LPS-induced secretion of IL-6 and
TNF-a, maximal activation was achieved by relatively low
concentrations of LPS, more specifically concentrations upwards
of 500 pg/ml. Therefore, when using these readouts to assess
potential immune activation properties of candidate molecules,
particularly endogenous danger signals, it is essential to almost
completely eliminate all of the LPS in the preparation in order to
circumvent artificial and misleading conclusions.
Interestingly, this study also found that secretion of IL-12p40
and particularly IL-12p70 by DCs is less sensitive to LPS than
secretion of IL-6 and TNF-a or surface expression of costimula-
tory and MHC molecules. More specifically, LPS concentrations
of 50 pg/ml and 500 pg/ml were required to promote minimal
secretion of IL-12p40 and IL-12p70 respectively, while maximal
secretion of these cytokines was achieved by stimulating DCs with
50ng/ml LPS. Therefore, there are different thresholds for
secretion of specific cytokines by DCs in response to LPS.
Ultimately, it is important for researchers to be vigilant of this
when assessing the immune activation properties of candidate
molecules.
The molecular weight of LPS can vary a great deal due to the
heterogeneity within the acyl chains and differential phosphory-
lation. In order to address this problem, the U.S. Food and Drug
Administration (FDA) have developed endotoxin units (EU) as an
alternative to units of weight. EU describes the biological activity
of LPS and a single EU is equal to approximately 100pg of E. coli
LPS, the amount present in 1 x 10
5 bacteria. Many research
laboratories use EU values to determine contaminating LPS
concentrations in sample preparations, particularly when using
limulus amebocyte lysate testing. It is important to note that
10 pg/ml LPS is equivalent to as little as 0.1 EU/ml.
The literature contains many studies reporting novel immunos-
timulatory properties for endogenous molecules, many of which
signal through TLR4. However, many of these reports fail to use
effective controls for residual LPS contamination.
Perhaps the most common control used to eliminate LPS
contamination is the Bacillus polymyxa-derived antibiotic PmB. PmB
possesses a very high binding affinity for the lipid A moiety of LPS,
thus serving to neutralise this PAMP and prevent interaction with
Figure 4. PmB exhibits a limited capacity to inhibit LPS-induced secretion of proinflammatory cytokines from BMDCs. BMDCs
(6.25610
5 cells/ml) from BALB/c mice were stimulated with concentrations from 1 pg/ml to 1mg/ml LPS, which were pre-incubated alone or in the
presence of PmB (100 mg/ml) for 2 hours at 37uC. Supernatants were collected 24 hours later and tested for IL-6 (A), TNF-a (B), IL-12p40 (C) and IL-
12p70 (D) by ELISA. Results are mean cytokine concentrations (+ SEM) for triplicate samples. Versus RPMI alone, *** p,0.001, LPS + PmB versus LPS
only,NNN p,0.001. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0037261.g004
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effects of DC activation are often neglected. This study has shown
that the assumption that the presence of PmB eliminates LPS-
mediated effects on DCs is inaccurate, and its effects are
dependent on both the concentration of LPS present and the
particular cytokines under investigation.
Many studies reporting immunomodulatory activity for endog-
enous danger signals routinely use a concentration of 10 mg/ml
Figure 5. LPS-induced expression of CD80 and CD40 is no longer completely inhibited by PmB at a concentration of 20ng/ml. (A)
BMDCs (6.25610
5 cells/ml) from BALB/c mice were stimulated with the indicated concentrations of LPS and CpG, which were pre-incubated alone or
in the presence of PmB (100 mg/ml) for 2 hours at 37uC. Cells were harvested 24 hours later and analysed for expression of CD80 and CD40 by flow
cytometry. Immunofluorescence is shown for LPS- or CpG-treated BMDCs (black line) compared to untreated cells incubated with medium (grey
histograms). (B) BMDCs (6.25610
5 cells/ml) from BALB/c mice were stimulated as described in Figure 5A. Cells were harvested 24 hours later and
analysed for expression of the maturation markers CD80 and CD40 by flow cytometry. Data is represented as median fluorescence intensity (MFI).
Data are representative of three independent experiments.
doi:10.1371/journal.pone.0037261.g005
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Indeed, higher concentrations of PmB are not normally used to
inhibit LPS-mediated DC activation due to concerns over toxicity.
By performing a dose response determination, this study has
shown that 10 mg/ml PmB is an appropriate concentration for
inhibiting LPS-induced DC activation without eliciting any
adverse effects on the cells. 50 mg/ml PmB induced partial
upregulation of CD80, CD40 and MHC II, whereas 100 mg/ml
PmB was toxic. Importantly, in this study, LPS was pre-incubated
with 100 mg/ml PmB for 2 hours at 37uC, thereby exposing LPS
to PmB concentrations ten-fold greater than the 10 mg/ml optimal
concentration determined here and also used in other studies.
However, once added to the DCs, the final concentration of PmB
was 10mg/ml which is non-toxic and does not enhance expression
of costimulatory or MHC II molecules.
The efficacy of PmB varied for different cytokines and was
ineffective for LPS concentrations greater than 20ng/ml in the
case of IL-6 and TNF-a. Therefore, not only can extremely low
concentrations of LPS induce secretion of IL-6 and TNF-a, but
PmB is also exceedingly limited in its capacity to successfully
reverse these effects. However, for IL-12p40 and IL-12p70, the
inhibitory properties of PmB were preserved until LPS concentra-
tions of 0.5 mg/ml and 1mg/ml were reached respectively. Despite
this, LPS-driven DC maturation was no longer completely
inhibited by PmB at LPS concentrations greater than 20 ng/ml,
thereby further emphasising the inadequacies of this control.
The common perception that LPS is heat resistant dates back to
the 19
th century when it was demonstrated by Richard Pfeifer that
heat-inactivated Vibrio cholera retained their ability to induce shock
in experimental animals. This led to a widely used method of
boiling protein preparations for at least 30 minutes to rule out LPS
contamination as the cause of the observed effects [33]. However,
this study has shown that secretion of IL-6 and IL-12p40 by
BMDCs in response to low concentrations of LPS is reduced by
heating at 60uC or 100uC.
These results support other studies which have shown that low
concentrations of heat treated E. coli LPS fail to promote TNF-
a secretion by murine macrophages [22–23]. Importantly, Gao
and colleagues outline that many studies use very high concentra-
tions of LPS, approximately 10–500 ng/ml, to test for heat
sensitivity. Since only minute concentrations of LPS are required
to fully activate an APC, Gao et al. propose that even if practically
all of the LPS is inactivated by heat treatment, the active residual
LPS is sufficient to activate an APC, thus leading to the incorrect
conclusion that LPS is heat resistant. In support of this idea, this
study found that a concentration of 50 pg/ml LPS was sufficient to
induce DC maturation and robust secretion of a number of
proinflammatory cytokines. Therefore, LPS is capable of pro-
moting DC activation at concentrations approximately two
hundred times less than the minimal concentrations being used
to test for heat sensitivity.
Many studies have reported that TLR agonists can synergise
with microbial and endogenous immunomodulators to enhance
BMDC secretion of specific proinflammatory cytokines, in
particular IL-6 [34–39]. This study hypothesised that extremely
low concentrations of LPS that are incapable of promoting
cytokine secretion independently can synergise with candidate
molecules to promote this effect. This ultimately generates the
incorrect conclusion that the candidate molecule can induce
cytokine secretion independently of LPS. Interestingly, this study
shows that a concentration as low as 5 pg/ml LPS alone is not
sufficient to promote secretion of IL-6 but can still synergise with
LT to promote IL-6 secretion. Crucially, LT alone was unable to
induce IL-6 secretion, thus raising the possibility that many
Figure 6. Heating low concentrations of LPS negates its ability
to modulate BMDC secretion of IL-6 and IL-12p40. BMDCs
(6.25610
5 cells/ml) from BALB/c mice were stimulated with control LPS
(50 pg/ml) (Ctrl) or heat-inactivated (HI) LPS (100uCo r6 0 uC for 1 hour).
Supernatants were collected 24 hours later and tested for IL-6 and IL-
12p40 by ELISA. Results are mean cytokine concentrations (+ SEM) for
triplicate samples. Versus RPMI alone, *** p,0.001. Data are represen-
tative of four independent experiments.
doi:10.1371/journal.pone.0037261.g006
Figure 7. LPS concentrations as low as 5pg/ml induce secretion
of IL-6 by murine BMDCs in the presence of E. coli heat-labile
enterotoxin. BMDCs (6.25610
5 cells/ml) from BALB/c mice were
stimulated with concentrations from 1pg/ml to 15pg/ml LPS, either
alone or in the presence of LT (0.1 mg/ml). Supernatants were collected
24 hours later and tested for IL-6 by ELISA. Results are mean cytokine
concentrations (+ SEM) for triplicate samples. LPS + LT versus LT only, *
p,0.05 *** p,0.001. Data are representative of five independent
experiments.
doi:10.1371/journal.pone.0037261.g007
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activity only as a direct result of synergy with low levels of
contaminating LPS. Furthermore, the effects of contaminating
LPS are also likely to result in misleading conclusions when using
other APCs, including macrophages.
In conclusion, this study has revealed that extremely low
concentrations of LPS can promote DC activation and that
different thresholds exist for secretion of specific cytokines in
response to this potent bacterial PAMP. Furthermore, PmB is
limited in its capacity to reverse the effects of residual LPS
contamination and is therefore an inadequate and unreliable
control. In light of both the potency of LPS and the inability of
PmB to efficiently neutralise this PAMP, it is necessary to
completely remove LPS from candidate immunostimulatory
molecules before using murine BMDC activation to test for
potential activity. However, the complete removal of LPS from
preparations is exceedingly difficult to accomplish, particularly for
proteins such as HMGB1 and certain Hsps that bind specifically to
this PAMP [35,49–50]. Therefore, in cases where removal of LPS
is not feasible we propose that the only definitive way to eliminate
the possibility of residual LPS contamination is to use TLR4-
deficient DCs or immortalised cell lines which do not express
TLR4. However, the obvious drawback to this method is that
genuine TLR4 agonists may evade discovery.
It is imperative that the potency of LPS in promoting DC
activation is fully appreciated and the limitations of many of the
controls for residual LPS contamination are not neglected. In
order to reliably identify novel immunostimulatory molecules
using dendritic cell models, these key issues must be addressed
appropriately.
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